Immune Focusing and Enhanced Neutralization Induced by HIV-1 gp140 Chemical Cross-Linking
Open Access
- 15 September 2013
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 87 (18) , 10163-10172
- https://doi.org/10.1128/jvi.01161-13
Abstract
Experimental vaccine antigens based upon the HIV-1 envelope glycoproteins (Env) have failed to induce neutralizing antibodies (NAbs) against the majority of circulating viral strains as a result of antibody evasion mechanisms, including amino acid variability and conformational instability. A potential vaccine design strategy is to stabilize Env, thereby focusing antibody responses on constitutively exposed, conserved surfaces, such as the CD4 binding site (CD4bs). Here, we show that a largely trimeric form of soluble Env can be stably cross-linked with glutaraldehyde (GLA) without global modification of antigenicity. Cross-linking largely conserved binding of all potent broadly neutralizing antibodies (bNAbs) tested, including CD4bs-specific VRC01 and HJ16, but reduced binding of several non- or weakly neutralizing antibodies and soluble CD4 (sCD4). Adjuvanted administration of cross-linked or unmodified gp140 to rabbits generated indistinguishable total gp140-specific serum IgG binding titers. However, sera from animals receiving cross-linked gp140 showed significantly increased CD4bs-specific antibody binding compared to animals receiving unmodified gp140. Moreover, peptide mapping of sera from animals receiving cross-linked gp140 revealed increased binding to gp120 C1 and V1V2 regions. Finally, neutralization titers were significantly elevated in sera from animals receiving cross-linked gp140 rather than unmodified gp140. We conclude that cross-linking favors antigen stability, imparts antigenic modifications that selectively refocus antibody specificity and improves induction of NAbs, and might be a useful strategy for future vaccine design.Keywords
This publication has 64 references indexed in Scilit:
- Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2Nature, 2012
- Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigensNature Biotechnology, 2012
- Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy TrialNew England Journal of Medicine, 2012
- Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architecturesProceedings of the National Academy of Sciences, 2011
- Expression-System-Dependent Modulation of HIV-1 Envelope Glycoprotein Antigenicity and ImmunogenicityJournal of Molecular Biology, 2010
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandNew England Journal of Medicine, 2009
- Molecular architecture of native HIV-1 gp120 trimersNature, 2008
- Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionProceedings of the National Academy of Sciences, 2008
- Structural definition of a conserved neutralization epitope on HIV-1 gp120Nature, 2007
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004